| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17460441.2010.511473 |
| P698 | PubMed publication ID | 22823992 |
| P2093 | author name string | Mellar P Davis | |
| P2860 | cites work | A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers | Q24530081 |
| G-protein-coupled receptor heterodimerization modulates receptor function | Q24603239 | ||
| Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain | Q28299786 | ||
| Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-beta-Ala, a novel dermorphin analogue with high affinity at mu-opioid receptors | Q28378301 | ||
| Opioids: first lessons from knockout mice | Q33547877 | ||
| Bi- or multifunctional opioid peptide drugs | Q33767037 | ||
| Endomorphins: novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density | Q33838460 | ||
| Pain inhibition by endomorphins | Q33838465 | ||
| The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists | Q33910425 | ||
| Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads | Q33980568 | ||
| Opioids and their complicated receptor complexes | Q34047403 | ||
| Development of opioid peptide analogs for pain relief | Q34089668 | ||
| Structure and regulation of opioid receptors | Q34136307 | ||
| Stereochemical requirements for receptor recognition of the mu-opioid peptide endomorphin-1. | Q34172320 | ||
| Identity of the putative δ1-opioid receptor as a δ–κ heteromer in the mouse spinal cord | Q34191890 | ||
| Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series | Q34244966 | ||
| Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids. | Q34409452 | ||
| Opioids in chronic pain | Q34430627 | ||
| FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity | Q44344666 | ||
| Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors | Q44346220 | ||
| Dimerization of the delta opioid receptor: implication for a role in receptor internalization | Q44347088 | ||
| In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance | Q44348499 | ||
| Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability | Q44351271 | ||
| Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers | Q44351287 | ||
| The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats | Q44352759 | ||
| Antinociceptive effect of a novel long-acting nalbuphine preparation | Q44788581 | ||
| Receptor binding and biological activity of bivalent enkephalins | Q46287132 | ||
| Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties. | Q46632226 | ||
| A topochemical approach to explain morphiceptin bioactivity | Q46848318 | ||
| Cyclic beta-casomorphin analogues with mixed mu agonist/delta antagonist properties: synthesis, pharmacological characterization, and conformational aspects | Q48139426 | ||
| Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. | Q48312659 | ||
| Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. | Q48634644 | ||
| Postoperative intravenous morphine consumption, pain scores, and side effects with perioperative oral controlled-release oxycodone after lumbar discectomy. | Q50975673 | ||
| Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine. | Q51982368 | ||
| G protein-induced trafficking of voltage-dependent calcium channels. | Q52567248 | ||
| Agonist-independent modulation of N-type calcium channels by ORL1 receptors. | Q54733725 | ||
| Improved bioavailability to the brain of glycosylated Met-enkephalin analogs | Q56114253 | ||
| Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. | Q34489836 | ||
| Opioid Agonist-Antagonist Drugs in Acute and Chronic Pain States | Q34582848 | ||
| Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects | Q34585824 | ||
| Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications | Q34607999 | ||
| (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties | Q34656455 | ||
| Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors | Q34751702 | ||
| LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential | Q34763263 | ||
| Current prodrug strategies via membrane transporters/receptors | Q34779782 | ||
| Oligomerization of opioid receptors | Q34826270 | ||
| Structure-activity relationship, conformation and pharmacology studies of morphiceptin analogues--selective mu-opioid receptor ligands | Q34948349 | ||
| Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile | Q34983352 | ||
| Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain | Q34996809 | ||
| Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood-brain barrier penetration | Q35027860 | ||
| Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. | Q35616945 | ||
| Enter a new post-translational modification: D-amino acids in gene-encoded peptides | Q35624017 | ||
| Peripherally restricted opioid agonists as novel analgesic agents | Q35699409 | ||
| Molecular biology of opioid analgesia | Q36134120 | ||
| Endogenous opiates and behavior: 2004. | Q36205185 | ||
| Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters | Q36307818 | ||
| Targeting opioid receptor heterodimers: strategies for screening and drug development | Q36439166 | ||
| Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence | Q36616315 | ||
| Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists | Q36628309 | ||
| New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores | Q36731648 | ||
| Kappa receptor bivalent ligands. | Q36737996 | ||
| Agonist-specific regulation of mu-opioid receptor desensitization and recovery from desensitization | Q36807249 | ||
| Agmatine and imidazoline receptors: their role in opioid analgesia, tolerance and dependence | Q36892267 | ||
| Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands | Q37159251 | ||
| Multiple ligands in opioid research | Q37265078 | ||
| A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists | Q37333022 | ||
| Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists | Q37342344 | ||
| Designing multiple ligands - medicinal chemistry strategies and challenges | Q37387562 | ||
| Design of multivalent ligand targeting G-protein-coupled receptors | Q37387581 | ||
| Membrane functional organisation and dynamic of mu-opioid receptors | Q37419004 | ||
| Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications | Q37444456 | ||
| Tapentadol immediate release for the relief of moderate-to-severe acute pain | Q37606489 | ||
| Delta and kappa opioid receptors as suitable drug targets for pain | Q37660843 | ||
| Recent developments in the design of receptor specific opioid peptides | Q38282505 | ||
| Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide | Q38300930 | ||
| Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients | Q39334344 | ||
| Dying from cancer: results of a national population-based investigation | Q39417667 | ||
| Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability | Q39428676 | ||
| Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. | Q39779553 | ||
| Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties | Q39793785 | ||
| Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier | Q40960259 | ||
| A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. | Q41978227 | ||
| Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity | Q42014419 | ||
| Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for mu opioid and I2-imidazoline receptors: synthesis and pharmacological screening. | Q42165684 | ||
| Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study | Q42167015 | ||
| Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain | Q42379212 | ||
| Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis | Q42691918 | ||
| mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). | Q43287655 | ||
| NT69L, a novel analgesic, shows synergy with morphine | Q43299481 | ||
| Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial | Q43340074 | ||
| [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine | Q43892437 | ||
| Dermorphin and deltorphin heptapeptide analogues: replacement of Phe residue by Dmp greatly improves opioid receptor affinity and selectivity | Q43962766 | ||
| Endomorphin-1 analogues containing beta-proline are mu-opioid receptor agonists and display enhanced enzymatic hydrolysis resistance | Q44010088 | ||
| In vitro quantitative study of the degradation of endomorphins | Q44129032 | ||
| Simultaneous activation of the delta opioid receptor (deltaOR)/sensory neuron-specific receptor-4 (SNSR-4) hetero-oligomer by the mixed bivalent agonist bovine adrenal medulla peptide 22 activates SNSR-4 but inhibits deltaOR signaling | Q44330346 | ||
| Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity | Q44330959 | ||
| Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites | Q44331089 | ||
| Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties | Q44331872 | ||
| Beta-casomorphins: substitution of phenylalanine with beta-homo phenylalanine increases the mu-type opioid receptor affinity | Q44332043 | ||
| Synthesis of stereoisomeric analogues of endomorphin-2, H-Tyr-Pro-Phe-Phe-NH(2), and examination of their opioid receptor binding activities and solution conformation | Q44333208 | ||
| Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2). | Q44333625 | ||
| Arylacetamides as peripherally restricted kappa opioid receptor agonists | Q44333858 | ||
| Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores | Q44334464 | ||
| From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes | Q44335899 | ||
| Analgesic activity of a novel bivalent opioid peptide compared to morphine via different routes of administration | Q44336454 | ||
| Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists | Q44336565 | ||
| Update on opioid receptors. | Q44336699 | ||
| Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. | Q44339568 | ||
| Dermorphin analogues carrying an increased positive net charge in their "message" domain display extremely high mu opioid receptor selectivity | Q44339837 | ||
| Structural models for dimerization of G-protein coupled receptors: the opioid receptor homodimers. | Q44340332 | ||
| Attenuation of morphine tolerance and dependence with the highly selective delta-opioid receptor antagonist TIPP[psi]. | Q44341172 | ||
| Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain | Q44341214 | ||
| Two distinct mechanisms mediate acute mu-opioid receptor desensitization in native neurons. | Q44341856 | ||
| Efforts aim to curb opioid deaths, injuries | Q44342053 | ||
| Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors | Q44343448 | ||
| Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for mu-opioid receptors and I2-imidazoline binding sites. | Q44344013 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pain management | Q621261 |
| P304 | page(s) | 1007-1022 | |
| P577 | publication date | 2010-08-15 | |
| P1433 | published in | Expert Opinion on Drug Discovery | Q5421204 |
| P1476 | title | Opioid receptor targeting ligands for pain management: a review and update | |
| P478 | volume | 5 |
| Q55716780 | Antinociceptive potency of a fluorinated cyclopeptide Dmt-c[D-Lys-Phe-p-CF3-Phe-Asp]NH2. |
| Q36274635 | Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives |
| Q44347360 | Efficacy and safety of dual opioid therapy |
| Q40269619 | Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations |
Search more.